Alberta Investment Management Corp grew its stake in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 50.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,661,616 shares of the company’s stock after buying an additional 554,900 shares during the period. Alberta Investment Management Corp’s holdings in Kenvue were worth $28,663,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Kenvue by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 234,951,484 shares of the company’s stock worth $4,052,913,000 after purchasing an additional 1,604,040 shares during the last quarter. State Street Corp increased its position in shares of Kenvue by 3.5% in the fourth quarter. State Street Corp now owns 118,865,134 shares of the company’s stock worth $2,050,424,000 after purchasing an additional 4,063,257 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Kenvue by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 49,862,574 shares of the company’s stock worth $856,778,000 after purchasing an additional 371,322 shares during the last quarter. Norges Bank bought a new position in shares of Kenvue in the fourth quarter worth approximately $756,862,000. Finally, American Century Companies Inc. increased its position in shares of Kenvue by 22.4% in the third quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock worth $601,267,000 after purchasing an additional 6,781,640 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.
Insider Buying and Selling at Kenvue
In other news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.59% of the company’s stock.
Analyst Upgrades and Downgrades
Read Our Latest Stock Report on KVUE
Kenvue Stock Performance
NYSE:KVUE opened at $18.25 on Tuesday. The firm has a market cap of $35.03 billion, a PE ratio of 21.47, a price-to-earnings-growth ratio of 1.38 and a beta of 0.54. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $22.87. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. The business has a 50 day moving average price of $17.45 and a 200-day moving average price of $17.55.
Kenvue (NYSE:KVUE – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion during the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.24 earnings per share. Equities research analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current year.
Kenvue Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were paid a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.5%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio is 97.65%.
Kenvue Profile
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Featured Articles
- Five stocks we like better than Kenvue
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
